Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience

Area of Science:

• Medical Oncology
• Surgical Oncology
• Clinical Trials

Background:

• The Scandinavian Sarcoma Group (SSG) has conducted multiple chemotherapy studies for soft tissue sarcoma (STS) since 1981.
• Initial studies (SSG I) using single-agent doxorubicin showed no survival benefit in high-grade STS.
• Subsequent studies (SSG X) explored more intensive regimens like ifosfamide and etoposide, showing high response rates and suggesting survival benefits with preoperative chemotherapy.

Purpose of the Study:

• To evaluate the efficacy of adjuvant ifosfamide and doxorubicin treatment in patients with high-risk soft tissue sarcoma after primary surgery.
• To determine if this adjuvant therapy improves disease-free survival and overall survival in selected STS patients with unfavorable prognostic factors.

Main Methods:

• Phase 2 study design (SSG XIII) initiated on July 1, 1998.
• Focus on selected patients with high-grade STS and other unfavorable prognostic criteria.
• Administration of adjuvant ifosfamide and doxorubicin following primary surgical resection.

Main Results:

• SSG I (1981) found no improvement in overall or disease-free survival with adjuvant doxorubicin.
• SSG X (1991-1994) demonstrated a high response rate (42%) with ifosfamide and etoposide, with preliminary data suggesting increased survival after preoperative chemotherapy.
• A meta-analysis including SSG I indicated improved disease-free survival and potential overall survival benefits from adjuvant chemotherapy in localized resectable STS.

Conclusions:

• Early SSG trials did not establish a clear benefit for single-agent adjuvant doxorubicin in high-grade STS.
• More intensive chemotherapy regimens and preoperative approaches show promise, warranting further investigation.
• The ongoing SSG XIII study aims to confirm the survival benefit of adjuvant ifosfamide and doxorubicin in high-risk STS patients.